Exploring Occupancy of Dopamine D3 Receptor by Buspirone in Humans Using PET
Status:
Completed
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
The objective of the present study is to use positron emission tomography brain imaging to
investigate D3 occupancy of buspirone, an FDA-approved anxiolytic which acts as a serotonin
partial agonist but has recently been identified as a D3 antagonist. It is hypothesized that
clinically relevant doses of buspirone will occupy the D3 receptor.